# Junta clínica — PT-pseudo_e9fbcdc890f2 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_e9fbcdc890f2",
  "pid": "PT-pseudo_e9fbcdc890f2",
  "task": 1,
  "psa": 82.0,
  "age": 74,
  "months": 2,
  "pirads": "5",
  "psad": 1.281,
  "psav": 9.76,
  "psap": 62.9,
  "vol": 64.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.9339169,
  "medhx": "Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis",
  "meds": "amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN",
  "notes": "PSA 82 ng/mL. PI-RADS 5. PSAD 1.28. Prostate volume 64 mL. csPCa 0.93.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Obesity (BMI >30)",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "96 kg",
    "height": "185 cm",
    "bmi": "28.0",
    "bp": "139/80 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (31 pack-yr, quit 2023)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Feb 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent PSA elevation warrants clinical reassessment after an earlier positive prostate biopsy."
    },
    {
      "s": "History",
      "t": "A 74-year-old married man residing with his partner works as a self-employed contractor in carpentry. Despite mild osteoarthritis, he maintains a rigorous exercise routine, completing five-kilometre runs three times weekly. His medical background includes hypertension, hypercholesterolaemia, and obesity (BMI >30). Current pharmacotherapy comprises amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, and paracetamol PRN. He is an ex-smoker with a cumulative exposure of 31 pack-years, having successfully ceased smoking in 2023. Lower urinary tract symptoms are present, quantified by an IPSS score of 14, though he denies haematuria, skeletal discomfort, or unexplained weight loss. Weekly alcohol intake reaches approximately 39 units. A recent pulmonary function assessment was conducted for routine COPD surveillance. Commuting over an hour by rail, he manages his daily medications independently, relying on his spouse for logistical support."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The gland presents as symmetrically enlarged, possessing a firm, smooth surface devoid of palpable irregularities or asymmetry. Systemic review remains unremarkable; vital parameters are stable, and examination reveals no peripheral lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "self-employed contractor (carpentry)",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up"
  ],
  "alcohol": "39 units / week (heavy)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 14/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_e9fbcdc890f2
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 82.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 1.281 ng/mL²
  - PSA velocity: 9.76 ng/mL/yr
  - Prior PSA: 62.9 ng/mL
  - Prostate volume: 64.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9339169 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis
  - Current medication: amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 82 ng/mL. PI-RADS 5. PSAD 1.28. Prostate volume 64 mL. csPCa 0.93.

Vitals: weight 96 kg, height 185 cm, BMI 28.0, BP 139/80 mmHg, HR 72 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2023).

Chief complaint: Persistent PSA elevation warrants clinical reassessment after an earlier positive prostate biopsy.

History: A 74-year-old married man residing with his partner works as a self-employed contractor in carpentry. Despite mild osteoarthritis, he maintains a rigorous exercise routine, completing five-kilometre runs three times weekly. His medical background includes hypertension, hypercholesterolaemia, and obesity (BMI >30). Current pharmacotherapy comprises amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, and paracetamol PRN. He is an ex-smoker with a cumulative exposure of 31 pack-years, having successfully ceased smoking in 2023. Lower urinary tract symptoms are present, quantified by an IPSS score of 14, though he denies haematuria, skeletal discomfort, or unexplained weight loss. Weekly alcohol intake reaches approximately 39 units. A recent pulmonary function assessment was conducted for routine COPD surveillance. Commuting over an hour by rail, he manages his daily medications independently, relying on his spouse for logistical support.

Physical examination: DRE: The gland presents as symmetrically enlarged, possessing a firm, smooth surface devoid of palpable irregularities or asymmetry. Systemic review remains unremarkable; vital parameters are stable, and examination reveals no peripheral lymphadenopathy or abdominal masses.

Patient info: self-employed contractor (carpentry); Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 39 units / week (heavy); exercise Running 3x/week, 5 km; IPSS score: 14/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.13 epistemic (95% band 0.29-0.82); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.23: PI-RADS 5, PSA 70.0, PSAD 0.67, age 68, DRE Normal -> DEFER (clear). He wrote: "This patient has PCa and a very high PSA. start treatment and do a PSMA-PET ."
  2. distance 2.08: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."
  3. distance 2.08: PI-RADS 5, PSA 187.0, PSAD 3.26, age 75, DRE Nodus -> BIOPSY (clear). He wrote: "Very High PSA. Most likely metastatic"

PRECEDENT: DEFER (weighted vote 0.27 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the use of MRI-directed biopsy and repeat biopsy after a negative biopsy. It states: "Do not perform confirmatory biopsies if a patient has had upfront magnetic resonance imaging (MRI) and targeted and perilesional biopsies."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your suggestion of biopsy is not settled by the guideline because the guideline does not account for the prior positive biopsy status as a decisive factor in this context. EXPERT-COHORT, your criterion based on a prior positive biopsy is not settled because the guideline does not provide a definitive threshold for when to defer based on that history alone.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: a positive biopsy means the indication for further tissue sampling is context-dependent based on current findings.
radiology_report - whether the lesion is compared against an earlier study: this is not specified, but the guideline suggests MRI-directed biopsy is the standard.
psa_trend - the PSA velocity: the guideline does not provide a specific threshold for PSA velocity in this scenario.
laboratory_results - the PSA density: the guideline suggests PSA density is a significant predictor in risk-adapted biopsy guidance.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on the context provided in the previous notes regarding the prior biopsy and the findings in the MRI report.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine the PSA velocity to assess against guideline suggestions.
  previous_notes (get_previous_notes) -> Determine the GRADE of the prior biopsy, the number and dates of biopsy sessions, and if a surveillance protocol is in place.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What was the GRADE (Gleason/ISUP) of the prior positive biopsy?
  Q2. Is the lesion in the radiology report compared against an earlier study?
  Q3. What is the PSA velocity, and does it meet any threshold suggested by the EAU guideline?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "circumscribed, hypointense focus in the right mid-gland peripheral zone spanning 22 x 18 x 15 mm."

psa_trend
PSA 2.0 (Jan 2023) rising to 82.0 (Feb 2025), steepest in the last year

previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: 1, on 05 Sep 2023
SURVEILLANCE: not recorded
TREATMENT: none recorded

WHAT I DID NOT OPEN
laboratory_results, family-history anamnesis, pathology report, because they were not explicitly requested by the plan.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 finding from the radiology report.
PSA velocity of 9.76 ng/mL/yr, which is a high velocity.

AGAINST sampling this patient now
Prior positive biopsy status, as per the previous notes.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 82.00 ng/mL over 5 points spanning 25 months; velocity +32.39 ng/mL per year; doubling time about 5 months.
PROJECTION at 6 months: 105.0 ng/mL, conformal 95% band 30.1-365.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.48
  uncertainty  +/- 0.11 epistemic (95% band 0.26-0.70), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.48  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.27  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule psa_ge_20; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).
Dissenting on the board: EXPERT-STRUCTURED. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—address the moderator's questions regarding the lesion comparison, PSA velocity, and prior biopsy details.

ALIGNMENT WITH THE PANEL
The panel protocol concluded NO BIOPSY based on the cohort criterion (PSA $\ge 20$ ng/mL), which was supported by the retrieved PSA velocity of $9.76 \text{ ng/mL/yr}$ (from the registrar's report) and the prior positive biopsy status noted in the previous notes.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What was the GRADE (Gleason/ISUP) of the prior positive biopsy? Not answered; the previous_notes state "PRIOR GRADE: not recorded."
Q2. Is the lesion in the radiology report compared against an earlier study? Answered; the radiology_report states "COMPARISON: new."
Q3. What is the PSA velocity, and does it meet any threshold suggested by the EAU guideline? Answered; the psa_trend shows a velocity of $9.76 \text{ ng/mL/yr}$, which is high, but the EAU guideline was not explicitly consulted for a threshold.

WHAT CARRIES WEIGHT, AND WHY
The PSA velocity ($9.76 \text{ ng/mL/yr}$) is important as it is a high velocity, supporting the cohort criterion that led to the panel's decision. The prior positive biopsy status is also critical contextually.

MY SUGGESTION TO THE CHAIR
Given that the panel protocol's answer rests on the cohort criterion, which was supported by the retrieved PSA velocity, the decision leans towards deferral, pending clarification on the prior biopsy grade.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

74y, PSA 82.0, PI-RADS 5, prior positive biopsy, and unrecorded prior grade dictate staging and treatment. The high PSA and known cancer status outweigh the PI-RADS 5 finding. No prior grade recorded prevents further tissue sampling. Treatment planning is indicated.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
